Low-dose colchicine to lower risk in leg artery disease
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether low-dose colchicine can reduce “residual” risk—future heart and blood-vessel problems—in people with peripheral artery disease (PAD). It targets PAD symptoms and complications like poor blood flow in the legs, even after certain procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re over 18 years old
- You have symptomatic peripheral artery disease in a leg, like painful walking limits, rest pain/foot wounds, or loss of tissue (gangrene/necrosis)
- Tests show poor leg blood flow or artery narrowing (ABI ≤ 0.90, or toe pressure/index if ankle arteries can’t be compressed)
- You’ve had a recent blood-flow procedure or amputation for artery disease, or you currently have severe symptoms like rest pain or tissue loss
- You can agree to join the study and return for follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a low-dose colchicine (LoDoCo) can help people with heart failure and inflammation feel better and exercise more. It is for adults 50 and older with HFpEF who have signs of inflammation in their blood.
This study tests whether a medication called colchicine can help prevent amputation in people with severe leg blood flow problems who just had surgery or a catheter procedure to restore blood flow. Colchicine is an anti-inflammatory drug that may help protect the leg tissue after treatment.
This trial tests whether a low dose of the anti-inflammatory drug colchicine can help people who have recently had a heart attack or unstable angina. It aims to see if colchicine reduces the risk of future heart problems.
This study tests whether a daily low dose of colchicine, a medicine used for gout and inflammation, can reduce inflammation and improve blood vessel and bone health in people with chronic kidney disease. It might help prevent complications like heart disease and weak bones.
This trial tests a combination pill (polypill) and a medicine called colchicine to see if they can lower the risk of future heart attacks, strokes, or other artery problems. It is for people who already have a history of heart or blood vessel disease.
This trial tests whether colchicine, a drug that reduces inflammation, can help prevent further heart problems or strokes in people with moderate chronic kidney disease. You may be eligible if you have kidney disease and have had a heart attack, stroke, or related event in the past.
Hear when a new Peripheral Arterial Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.